Caractérisation chimique et biologique de Waltheria indica L. (Malvaceae), herbacée utilisée en médecine traditionnelle au Burkina Faso pour la prise en charge de l'asthme

Au Burkina Faso, W. indica L. syn. W. americana est utilisée en médecine traditionnelle dans la prise en charge aussi bien curative que préventive de l'asthme. Basée sur une approche ethnopharmacologique, cette étude visait à caractériser W. indica sur le plan chimique et pharmacologique en relation avec l'usage traditionnel contre l'asthme. Méthodologie : Après avoir confirmé les données bibliographiques sur l'usage antiasthmatique de la plante par un entretien avec des tradipraticiens de santé, une recherche bioguidée a été réalisée. Des investigations chimiques à type d'extraction, de purification et de détermination structurale ont été conduites en alternance avec les investigations biologiques de laboratoire. En outre, une caractérisation in situ des groupes chimiques a été réalisée dans différentes parties de la plante. Puis, une évaluation de la toxicité générale aigue de l'extrait hydro alcoolique des racines a été réalisée chez la souris. Résultats et discussion : Des alcaloïdes et des polyphénols ont été mis en évidence dans les différentes parties de la plante. Plusieurs composés ont été isolés à partir de l'extrait hydro alcoolique (HA) des racines. Un seul a été identifié comme étant (-)-épicatéchine. HA, ses fractions n-hexane (F1), dichlorométhane (F2), acétate d'éthyle (F3), la fraction résiduelle (F4) et l'épicatéchine isolée de F3 inhibaient in vitro l'activité de la 5-LOX, la LOX-IB de soja et la PLA2 de manière dose dépendante. L'inhibition de la PDE4A1a par les fractions n'était pas dose dépendant. Sur le plan tissulaire, HA, F3 et les fractions dérivées de F3 inhibaient les contractions induites par l'acétylcholine sur la trachée de rat ex vivo. Un effet dose dépendant était observé avec une CI50 de 1051 g/mL pour HA, entre 181 et 477 g/mL pour F3 et ses fractions. HA est modérément toxique chez la souris par voie intrapéritonéale (DL50 =210 mg/Kg). Cette étude est la première investigation pharmacologique de l'usage traditionnel de W. indica contre l'asthme. Nos résultats supportent cet usage traditionnel de la plante et démontrent la participation de l'épicatéchine aux propriétés antiasthmatiques. Conclusion : La validation pharmacologique de l'usage traditionnel de W. indica contre l'asthme doit être complétée par les futures investigations précliniques avec l'isolement et les tests biologiques d'autres composés de la plante qui participeraient à l'activité de W. indica.In Burkina Faso, W. indica L. syn. W. americana is used by traditional healers for curative and preventive management of asthma. Based on an ethnopharmacological approach, this study aimed to characterize W. indica on the chemical and pharmacological level according to the traditional use against asthma. Methodology: First, interviews of traditional healers confirmed the literature data concerning traditional use of the plant against asthma. Second, chemical investigations were conducted alternatively with biological investigation. Moreover, an in situ characterization of mains chemical groups was performed in different parts of the plant; then, a general acute toxicity of hydro alcoholic extract was evaluated in mice. Results and discussion: Alkaloids and polyphenols are presents in different parts of W. indica. Several compounds have been isolated from hydro alcoholic roots extract (HA). One compound have been identified as (-)-epicatechin. In vitro, HA, its fractions n-hexane (F1), dichloromethane (F2), ethyl acetate (F3), residual fraction (F4) and (-)-epicatechin isolated from F3 dose-dependently inhibited the activity of 5-LOX, LOX-IB de soja and PLA2. Inhibition of PDE4A1a by fractions was not dose-dependent. On tissue level, HA, F3 and fractions from F3 inhibited contraction induced by acetylcholine on rat trachea ex vivo. This effect was dose-dependent with IC50 of 1051 g/mL for HA, between 181 and 477 g/mL for F3 and its fractions. HA is moderately toxic in mice (LD50 =210 mg/Kg, intraperitoneal route). This study is the first pharmacological investigation of traditional use of W. indica against asthma. Our results validate the use of W. indica in traditional for management of asthma. These effects should be, at least in part, attributed to the presence of (-)-epicatechin in roots of W. indica. Conclusion: The pharmacological validation of traditional use of W. indica against asthma must be completed in the future research by isolation and biological assays of other compounds which could participate to activity of W. indica.SAVOIE-SCD - Bib.électronique (730659901) / SudocGRENOBLE1/INP-Bib.électronique (384210012) / SudocGRENOBLE2/3-Bib.électronique (384219901) / SudocSudocFranceF

Role of hypoxia inducible factor-1α in remote limb ischemic preconditioning.

Remote ischemic preconditioning (RIPC) has emerged as a feasible and attractive therapeutic procedure for heart protection against ischemia/reperfusion (I/R) injury. However, its molecular mechanisms remain poorly understood. Hypoxia inducible factor-1α (HIF-1α) is a transcription factor that plays a key role in the cellular adaptation to hypoxia and ischemia. This study\u27s aim was to test whether RIPC-induced cardioprotection requires HIF-1α upregulation to be effective. In the first study, wild-type mice and mice heterozygous for HIF1a (gene encoding the HIF-1α protein) were subjected to RIPC immediately before myocardial infarction (MI). RIPC resulted in a robust HIF-1α activation in the limb and acute cardioprotection in wild-type mice. RIPC-induced cardioprotection was preserved in heterozygous mice, despite the low HIF-1α expression in their limbs. In the second study, the role of HIF-1α in RIPC was evaluated using cadmium (Cd), a pharmacological HIF-1α inhibitor. Rats were subjected to MI (MI group) or to RIPC immediately prior to MI (R-MI group). Cd was injected 18 0min before RIPC (Cd-R-MI group). RIPC induced robust HIF-1α activation in rat limbs and significantly reduced infarct size (IS). Despite Cd\u27s inhibition of HIF-1α activation, RIPC-induced cardioprotection was preserved in the Cd-R-MI group. RIPC applied immediately prior to MI increased HIF-1α expression and attenuated IS in rats and wild-type mice. However, RIPC-induced cardioprotection was preserved in partially HIF1a-deficient mice and in rats pretreated with Cd. When considered together, these results suggest that HIF-1α upregulation is unnecessary in acute RIPC

Activated plasma coagulation β-Factor XII-induced vasoconstriction in rats

By inducing BK (bradykinin)-stimulated adrenomedullary catecholamine release, bolus injection of the β-fragment of activated plasma coagulation Factor XII (β-FXIIa) transiently elevates BP (blood pressure) and HR (heart rate) of anaesthetized, vagotomized, ganglion-blocked, captopril-treated bioassay rats. We hypothesized that intravenous infusion of β-FXIIa into intact untreated rats would elicit a qualitatively similar vasoconstrictor response. BN (Brown Norway) rats received for 60 min either: (i) saline (control; n=10); (ii) β-FXIIa (85 ng/min per kg of body weight; n=9); or (iii) β-FXIIa after 2ADX (bilateral adrenalectomy; n=9). LV (left ventricular) volume and aortic BP were recorded before (30 min baseline), during (60 min) and after (30 min recovery) the infusion. TPR (total peripheral resistance) was derived from MAP (mean arterial pressure), SV (stroke volume) and HR. Saline had no haemodynamic effects. β-FXIIa infusion increased its plasma concentration 3-fold in both groups. In adrenally intact rats, β-FXIIa infusion increased MAP by 6% (5±2 mmHg) and TPR by 45% (0.50±0.12 mmHg/ml per min), despite falls in SV (−38±8 μl) and HR [−18±5 b.p.m. (beats/min)] (all P<0.05). In 2ADX rats, β-FXIIa had no HR effect, but decreased SV (−89±9 μl) and MAP (−4±1 mmHg), and increased TPR by 66% (0.59±0.15 mmHg/ml per min) (all P<0.05). After infusion, adrenally intact rats exhibited persistent vasoconstriction (MAP, 10±1 mmHg; TPR, 0.55±0.07 mmHg/ml per min; both P<0.05), whereas in 2ADX rats, MAP remained 5±1 mmHg below baseline (P<0.05) and TPR returned to baseline. End-study arterial adrenaline (epinephrine) concentrations in the three groups were 1.9±0.6, 9.8±4.1 and 0.6±0.2 nmol/l respectively. Thus, in neurally intact lightly anaesthetized untreated rats, β-FXIIa infusion induces both adrenal catecholamine-mediated and adrenally independent increases in peripheral resistance

COX-2: an in vivo evidence of its participation in heat stress-induced myocardial preconditioning.

International audienceOBJECTIVE: Heat stress (HS) is known to induce delayed protection against myocardial infarction. We have previously shown that inducible nitric oxide synthase (iNOS), was involved in mediating this form of preconditioning. Since iNOS and cyclooxygenase-2 (COX-2) are co-induced in various cell types, the goal of this study was to investigate whether COX-2 could also participate to the HS-induced cardioprotection. METHODS AND RESULTS: A total of 78 male Wistar rats, subjected to either heat stress (42 degrees C for 15 min) or sham anaesthesia were used for this study. Twenty-four hours later, they were treated or not with a selective COX-2 inhibitor, either celecoxib (3 mg kg(-1), i.p.) or NS-398 (5 mg kg(-1), i.p.), 30 min before being subjected to a 30-min occlusion of the left coronary artery followed by a 120-min reperfusion, in vivo. HS resulted in a marked increase in myocardial COX-2 protein expression at 24 h, associated with a significant protection against infarction (46.0+/-1.4% in sham vs. 26.8+/-3.8% in HS group) (

Soumission du dossier d'enregistrement selon l'E-CTD (exemple du rapport d'étude clinique)

GRENOBLE1-BU Médecine pharm. (385162101) / SudocSudocFranceF

Les aphtes buccaux (données actuelles et rôle du pharmacien)

GRENOBLE1-BU Médecine pharm. (385162101) / SudocSudocFranceF

New insight into the signalling pathways of heat stress-induced myocardial preconditioning: protein kinase Cepsilon translocation and heat shock protein 27 phosphorylation.

International audience1. Heat stress (HS) is known to induce delayed preconditioning against myocardial infarction 24 h later, but the exact signalling pathway of this response remains to be elucidated. In previous studies, we have shown evidence for the implication of protein kinase C (PKC) and p38 mitogen-activated protein kinase (MAPK) in the HS-induced reduction in infarct size. Furthermore, in their phosphorylated state, small heat shock proteins (Hsp27) seem to confer cytoskeletal protection. In the present study, we sought to determine the effect of HS on the subcellular distribution of PKC isoforms and on Hsp27 phosphorylation. 2. Rats were subjected to either HS (42 degrees C for 15 min; HS group) or sham anaesthesia (sham group) before their hearts were excised. Myocardial tissue extracts obtained 20 min or 24 h after HS were processed for western blot analysis. 3. In the HS group, PKCepsilon translocated from the cytosolic to the particulate fraction (4426 +/- 128 vs 6258 +/- 316 arbitrary units; P = 0.002). Chelerythrine (5 mg/kg, i.p.), a PKC inhibitor, abolished this translocation. Western blot analysis of Hsp27 24 h after HS showed a marked increase in protein expression and phosphorylation in the particulate fraction. 4. In the present study, we have shown that HS induces the translocation of PKCepsilon from the cytosolic to the particulate fraction. Along with our previous observation that PKC is a trigger of HS-induced myocardial preconditioning, the results of the present study suggest an important role of the epsilon isoform of PKC in this cardioprotective mechanism. Furthermore, we have also demonstrated that the cytoprotective protein Hsp27 is phosphorylated following HS. Therefore, we can conclude that PKC and MAPK/Hsp27 are involved in the signalling pathway of HS-induced cardioprotection

Traitement hormonal substitutif et prévention de l'ostéoporose

GRENOBLE1-BU Médecine pharm. (385162101) / SudocSudocFranceF

Intérêt des études précliniques in vitro de stabilité métabolique dans la sélection des nouvelles entités chimiques

Les études de métabolisme in vitro jouent un rôle prépondérant dans la sélection des nouvelles entités chimiques. Les investigations faites par les chercheurs consistent à comprendre les mécanismes d'absorption, de distribution, d'élimination et surtout les interactions avec les enzymes clé du métabolisme, les monooxygénases à cytochromes P450. L'étude de métabolisme in vitro est réalisée en phase préclinique du développement du médicament. Elle consiste à évaluer sur microsomes hépatiques humains la stabilité ou clairance métabolique des nouvelles molécules en étudiant les cinétiques de biotransformation en conditions oxydatives. Cette étude, qui doit être rapide, performante et discriminante pour les composés testés, a été mise au point dans l'objectif de travailler de façon parallèle avec les chimistes, qui pourront ainsi optimiser la structure chimique des molécules jusqu'à obtention d'une stabilité satisfaisante. Le protocole d'étude in vitro de stabilité métabolique humaine utilisé en laboratoire requiert une validation préalable avant son utilisation en routine. Ce protocole a été optimisé en terme de durée d'incubation et de choix du paramètre de stabilité in vitro. De plus, l'obtention d'une corrélation positive entre les paramètres déduits in vitro sur microsomes et ceux mesurés chez l'homme in vivo a permis d'apprécier la qualité du modèle utilisé. La courbe obtenue montrant des paramètres bien corrélés pourra servir d'outil d'extrapolation théorique de la clairance métabolique in vivo à partir de données estimées in vitro. Le nombre d'études in vivo humaines longues et coûteuses, sera diminué et le nombre de molécules testées plus important, ce qui augmentera les chances de sélectionner la bonne pour le développement clinique.GRENOBLE1-BU Médecine pharm. (385162101) / SudocSudocFranceF